Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial

Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in spec...

Full description

Saved in:
Bibliographic Details
Published inCurrent controlled trials in cardiovascular medicine Vol. 21; no. 1; pp. 872 - 14
Main Authors Montealegre, Jane R., Anderson, Matthew L., Hilsenbeck, Susan G., Chiao, Elizabeth Y., Cantor, Scott B., Parker, Susan L., Daheri, Maria, Bulsara, Shaun, Escobar, Betsy, Deshmukh, Ashish A., Jibaja-Weiss, Maria L., Zare, Mohammed, Scheurer, Michael E.
Format Journal Article
LanguageEnglish
Published London BioMed Central 21.10.2020
BioMed Central Ltd
BMC
Subjects
Biomedicine
Cancer screening
Cervical cancer
Cervical cancer screening
Clinical trials
Cost analysis
Cultural differences
Design
Diagnosis
Disease prevention
Early Detection of Cancer
Ethnicity
Evaluation
Female
Health care access
Health care policy
Health Sciences
Hispanic Americans
Human papillomavirus
Humans
Hybrid effectiveness-implementation designs
Hybrid type 2 designs
Intervention
Literacy
Mass Screening
Medical screening
Medical testing products
Medicine
Medicine & Public Health
Methods
Minority & ethnic groups
Minority Groups
Pap smear
Papillomaviridae
Papillomavirus infections
Papillomavirus Infections - diagnosis
Patient navigation
Patients
Pragmatic trials
Preventive medicine
Prospective Studies
Randomized Controlled Trials as Topic
Self-sample HPV testing
Statistics for Life Sciences
Study Protocol
Uterine Cervical Neoplasms - diagnosis
Womens health
United States
United States > US
Cervical cancer screening
Hybrid type 2 designs
Hybrid effectiveness-implementation designs
Patient navigation
Self-sample HPV testing
Pragmatic trials
Online AccessGet full text
ISSN1745-6215
1745-6215
DOI10.1186/s13063-020-04790-5

Cover

Abstract Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. Methods/design The Pr ospective E valuation of S elf- T esting to I ncrease S creening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n  = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n  = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n  = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. Discussion Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer. Trial registration ClinicalTrials.gov NCT03898167 . Registered on 01 April 2019. Trial status Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
AbstractList Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. The Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer.
Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation.BACKGROUNDAlmost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation.The Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness.METHODS/DESIGNThe Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness.Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer.DISCUSSIONHybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer.ClinicalTrials.gov NCT03898167 . Registered on 01 April 2019.TRIAL REGISTRATIONClinicalTrials.gov NCT03898167 . Registered on 01 April 2019.Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).TRIAL STATUSStudy start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
BackgroundAlmost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation.Methods/designThe Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness.DiscussionHybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer.Trial registrationClinicalTrials.gov NCT03898167. Registered on 01 April 2019.Trial statusStudy start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. Methods/design The Pr ospective E valuation of S elf- T esting to I ncrease S creening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n  = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n  = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n  = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. Discussion Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer. Trial registration ClinicalTrials.gov NCT03898167 . Registered on 01 April 2019. Trial status Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. Methods/design The Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. Discussion Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer. Trial registration ClinicalTrials.gov NCT03898167. Registered on 01 April 2019. Trial status Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020). Keywords: Cervical cancer screening, Self-sample HPV testing, Patient navigation, Hybrid effectiveness-implementation designs, Hybrid type 2 designs, Pragmatic trials
Abstract Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. Methods/design The Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. Discussion Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer. Trial registration ClinicalTrials.gov NCT03898167 . Registered on 01 April 2019. Trial status Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. The Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer. ClinicalTrials.gov NCT03898167 . Registered on 01 April 2019. Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
ArticleNumber 872
Audience Academic
Author Deshmukh, Ashish A.
Scheurer, Michael E.
Jibaja-Weiss, Maria L.
Chiao, Elizabeth Y.
Parker, Susan L.
Montealegre, Jane R.
Anderson, Matthew L.
Bulsara, Shaun
Escobar, Betsy
Zare, Mohammed
Cantor, Scott B.
Hilsenbeck, Susan G.
Daheri, Maria
Author_xml – sequence: 1
  givenname: Jane R.
  orcidid: 0000-0002-0840-9316
  surname: Montealegre
  fullname: Montealegre, Jane R.
  email: jrmontea@bcm.edu
  organization: Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
– sequence: 2
  givenname: Matthew L.
  surname: Anderson
  fullname: Anderson, Matthew L.
  organization: Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida
– sequence: 3
  givenname: Susan G.
  surname: Hilsenbeck
  fullname: Hilsenbeck, Susan G.
  organization: Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Department of Medicine, Baylor College of Medicine
– sequence: 4
  givenname: Elizabeth Y.
  surname: Chiao
  fullname: Chiao, Elizabeth Y.
  organization: Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Harris Health System
– sequence: 5
  givenname: Scott B.
  surname: Cantor
  fullname: Cantor, Scott B.
  organization: Department of Health Services Research, The University of Texas MD Anderson Cancer Center
– sequence: 6
  givenname: Susan L.
  surname: Parker
  fullname: Parker, Susan L.
  organization: Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
– sequence: 7
  givenname: Maria
  surname: Daheri
  fullname: Daheri, Maria
  organization: Harris Health System
– sequence: 8
  givenname: Shaun
  surname: Bulsara
  fullname: Bulsara, Shaun
  organization: Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
– sequence: 9
  givenname: Betsy
  surname: Escobar
  fullname: Escobar, Betsy
  organization: Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
– sequence: 10
  givenname: Ashish A.
  surname: Deshmukh
  fullname: Deshmukh, Ashish A.
  organization: Center for Health Services Research, Department of Management, Policy, and Community Health, The University of Texas School of Public Health
– sequence: 11
  givenname: Maria L.
  surname: Jibaja-Weiss
  fullname: Jibaja-Weiss, Maria L.
  organization: Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, School of Health Professions, Baylor College of Medicine
– sequence: 12
  givenname: Mohammed
  surname: Zare
  fullname: Zare, Mohammed
  organization: Harris Health System, Department of Family and Community Medicine, The University of Texas McGovern School of Medicine
– sequence: 13
  givenname: Michael E.
  surname: Scheurer
  fullname: Scheurer, Michael E.
  organization: Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33087164$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1DAUjVARfcAPsECW2LBJ8SOxHRZIVQW0UhEsKraW41zPuCT2YHtGGj6M78PplL6EKi98ZZ9z7uscVns-eKiq1wQfEyL5-0QY5qzGFNe4ER2u22fVARFNW3NK2r178X51mNIVxg3rWPOi2mcMS0F4c1D9-ardCANKMNo66Wk1Ajr7_gNlSNn5BfrpckI5IDetYtgAMhA3zugRGe1LjJKJAH5GOo80StpC3iIPGS1Bj3mJ0jZlmD6gQs_BhBHZEAtwue2jGxBYCya7DXhIqXZz-gl81tkFj6L2Q5jc71KeCT7HMM6V5uj0-LJ6bvWY4NXNfVRdfv50eXpWX3z7cn56clEbjkWuSdc3piV9BxhbYcQgpdFWWKZbsAKoIaYxgxQtH6TVTd9RK0QjJMaCDo1kR9X5TnYI-kqtopt03Kqgnbp-CHGhdMzOjKC4IZRwzXtW5iqxlNBrboztDTWcd7Rofdxprdb9BIMpbUY9PhB9-OPdUi3CRom21IO7IvDuRiCGX-uyHzW5ZGActYewToo2LeOynbd8VL19BL0K6-jLpBSVhDLCaCfvUAtdGnDehpLXzKLqhLOupZR2bUEd_wdVzgCTK3sBWwz0kPDmfqO3Hf4zXQHQHcDEkFIEewshWM3OVjtnq-Jsde1sNavKRyTjdj4p5bjxaSrbUVPJ4xcQ76bxBOsvdS0QMA
CitedBy_id crossref_primary_10_1136_ijgc_2022_003703
crossref_primary_10_1016_j_amepre_2023_10_020
crossref_primary_10_7554_eLife_84664
crossref_primary_10_1016_j_rmclc_2024_03_003
crossref_primary_10_1016_j_annemergmed_2024_10_002
crossref_primary_10_1089_whr_2024_0121
crossref_primary_10_1093_jnci_djac035
crossref_primary_10_1186_s12905_023_02448_3
crossref_primary_10_1016_j_jogn_2023_05_114
Cites_doi 10.1016/j.ygyno.2007.01.023
10.1038/bjc.2011.48
10.1186/1748-5908-8-139
10.1136/bmj.h2147
10.1002/ijc.28545
10.1186/1748-5908-6-111
10.1016/j.ejca.2015.07.006
10.1007/s10903-015-0287-9
10.1097/MLR.0b013e3182408812
10.1023/A:1018435522475
10.1158/1055-9965.EPI-14-0998
10.1001/jama.2018.8024
10.1371/journal.pone.0151978
10.1097/AOG.0b013e3182883a34
10.1093/pubmed/fdt057
10.2105/AJPH.85.6.791
10.1016/j.jbi.2019.103208
10.1111/j.1525-1497.2003.20807.x
10.1136/sti.2004.011858
10.1158/1055-9965.EPI-15-1044
10.1186/s13012-017-0640-6
10.1093/oxfordjournals.aje.a010166
10.1684/bdc.2011.1388
10.1016/j.cct.2017.11.004
10.1186/1748-5908-4-50
10.1038/sj.bjc.6605194
10.1016/j.pec.2014.09.003
10.1002/cncr.23756
10.1158/1055-9965.EPI-11-0307
10.1038/sj.bjc.6606040
10.1016/j.jbi.2008.08.010
10.1002/ijc.21955
10.1016/j.ypmed.2017.05.004
10.1016/j.psychres.2019.112513
10.1056/NEJMhpr1608578
10.3322/caac.20111
10.1097/AOG.0000000000000669
10.15585/mmwr.mm6608a1
10.1186/s12885-016-2859-z
10.3747/co.21.1720
10.1186/1748-5908-8-117
10.1371/journal.pone.0172548
10.1016/j.ypmed.2014.04.011
10.1016/j.vaccine.2012.07.056
10.1136/bmj.c1040
10.1007/s11524-006-9030-0
10.1016/j.amepre.2008.04.002
10.1002/ijc.26128
10.5888/pcd13.160225
10.1038/bjc.2011.236
10.1002/ijc.22484
10.1016/S1470-2045(10)70230-8
ContentType Journal Article
Copyright The Author(s) 2020
COPYRIGHT 2020 BioMed Central Ltd.
The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13063-020-04790-5
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
Medical Database ProQuest
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database



MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1745-6215
EndPage 14
ExternalDocumentID oai_doaj_org_article_6c1216a6b31648088eba6ccfbc2c6692
PMC7580009
A639522295
33087164
10_1186_s13063_020_04790_5
Genre Clinical Trial Protocol
Journal Article
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: National Institute for Minority Health and Health Disparities (US)
  grantid: R01MD013715
– fundername: NIMHD NIH HHS
  grantid: R01 MD013715
– fundername: ;
  grantid: R01MD013715
GroupedDBID ---
0R~
123
2-G
29Q
2WC
53G
5VS
6PF
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACUHS
ADBBV
ADRAZ
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHYZX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NAPCQ
O5R
O5S
OVT
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
WOQ
WOW
~8M
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
5GY
7XB
8FK
AHMBA
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
XSB
7X8
5PM
ID FETCH-LOGICAL-c607t-19b4c51b9e00f7c7d88caf7f3a5ef7e2c1c4cd8756d8fa4b92f774780072d483
IEDL.DBID M48
ISSN 1745-6215
IngestDate Wed Aug 27 01:27:48 EDT 2025
Thu Aug 21 14:07:13 EDT 2025
Fri Sep 05 11:09:11 EDT 2025
Fri Jul 25 04:12:33 EDT 2025
Tue Jun 17 21:12:31 EDT 2025
Tue Jun 10 20:50:00 EDT 2025
Mon Jul 21 05:51:42 EDT 2025
Tue Jul 01 04:00:49 EDT 2025
Thu Apr 24 23:05:32 EDT 2025
Sat Sep 06 07:26:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Cervical cancer screening
Hybrid type 2 designs
Hybrid effectiveness-implementation designs
Patient navigation
Self-sample HPV testing
Pragmatic trials
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c607t-19b4c51b9e00f7c7d88caf7f3a5ef7e2c1c4cd8756d8fa4b92f774780072d483
Notes ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0002-0840-9316
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13063-020-04790-5
PMID 33087164
PQID 2812313298
PQPubID 44365
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_6c1216a6b31648088eba6ccfbc2c6692
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7580009
proquest_miscellaneous_2453685004
proquest_journals_2812313298
gale_infotracmisc_A639522295
gale_infotracacademiconefile_A639522295
pubmed_primary_33087164
crossref_primary_10_1186_s13063_020_04790_5
crossref_citationtrail_10_1186_s13063_020_04790_5
springer_journals_10_1186_s13063_020_04790_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-10-21
PublicationDateYYYYMMDD 2020-10-21
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-21
  day: 21
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Current controlled trials in cardiovascular medicine
PublicationTitleAbbrev Trials
PublicationTitleAlternate Trials
PublicationYear 2020
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References SJ Curry (4790_CR25) 2018; 320
M Watson (4790_CR4) 2017; 100
G Bouchard-Fortier (4790_CR24) 2014; 36
TA Ghebreyesus (4790_CR58) 2019
HW Chesson (4790_CR2) 2012; 30
M Watson (4790_CR31) 2008; 113
MEAS Lewin (4790_CR29) 2000
EK Proctor (4790_CR59) 2013; 8
AG Bais (4790_CR20) 2007; 120
J Cuzick (4790_CR54) 2006; 119
K Sanner (4790_CR16) 2009; 101
G Broberg (4790_CR22) 2014; 134
LW Green (4790_CR42) 1980
J Tota (4790_CR12) 2014; 21
WK Huh (4790_CR46) 2015; 125
DT Janerich (4790_CR6) 1995; 85
A Crawford (4790_CR10) 2016; 13
DA Chambers (4790_CR38) 2013; 8
P Giorgi Rossi (4790_CR15) 2011; 104
A Szarewski (4790_CR57) 2011; 104
VT Nghiem (4790_CR50) 2016; 25
W Yoo (4790_CR33) 2017; 12
NNA Howlader (4790_CR5) 2015
PA Harris (4790_CR48) 2019; 95
SJ Landes (4790_CR39) 2019; 280
RP Bosgraaf (4790_CR9) 2014; 64
P Petignat (4790_CR27) 2007; 105
VB Benard (4790_CR7) 2014; 63
MS Goel (4790_CR8) 2003; 18
LS Massad (4790_CR45) 2013; 121
A Virtanen (4790_CR19) 2011; 20
AN Ogunwale (4790_CR11) 2016; 18
RC Baron (4790_CR35) 2008; 35
A White (4790_CR3) 2017; 66
L Gustafsson (4790_CR1) 1997; 8
M Tranberg (4790_CR21) 2016; 16
DA Chokshi (4790_CR30) 2016; 375
GS Ogilvie (4790_CR26) 2005; 81
PA Harris (4790_CR47) 2009; 42
I Wikstrom (4790_CR17) 2011; 105
ED Paskett (4790_CR36) 2011; 61
HP Freeman (4790_CR34) 2006; 83
Centers for Disease Control and Prevention (CDC) (4790_CR32) 2012; 61
L Piana (4790_CR18) 2011; 98
4790_CR52
M Gok (4790_CR13) 2010; 340
S de Sanjose (4790_CR49) 2010; 11
4790_CR60
ER Myers (4790_CR53) 2000; 151
E Enerly (4790_CR23) 2016; 11
F Verdoodt (4790_CR55) 2015; 51
K Rozemeijer (4790_CR51) 2015; 24
GA Aarons (4790_CR40) 2017; 12
M Gok (4790_CR14) 2012; 130
LJ Damschroder (4790_CR41) 2009; 4
JR Montealegre (4790_CR44) 2014; 97
GM Curran (4790_CR37) 2012; 50
K Loudon (4790_CR43) 2015; 350
RL Winer (4790_CR28) 2018; 64
MC Brouwers (4790_CR56) 2011; 6
References_xml – volume: 105
  start-page: 530
  issue: 2
  year: 2007
  ident: 4790_CR27
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2007.01.023
– volume: 104
  start-page: 915
  issue: 6
  year: 2011
  ident: 4790_CR57
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.48
– volume: 8
  start-page: 139
  year: 2013
  ident: 4790_CR59
  publication-title: Implement Sci
  doi: 10.1186/1748-5908-8-139
– volume: 350
  start-page: h2147
  year: 2015
  ident: 4790_CR43
  publication-title: BMJ
  doi: 10.1136/bmj.h2147
– volume: 134
  start-page: 2223
  issue: 9
  year: 2014
  ident: 4790_CR22
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28545
– volume: 6
  start-page: 111
  issue: 1
  year: 2011
  ident: 4790_CR56
  publication-title: Implement Sci
  doi: 10.1186/1748-5908-6-111
– volume: 51
  start-page: 2375
  issue: 16
  year: 2015
  ident: 4790_CR55
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.07.006
– volume: 18
  start-page: 1404
  issue: 6
  year: 2016
  ident: 4790_CR11
  publication-title: J Immigr Minor Health
  doi: 10.1007/s10903-015-0287-9
– volume: 50
  start-page: 217
  issue: 3
  year: 2012
  ident: 4790_CR37
  publication-title: Med Care
  doi: 10.1097/MLR.0b013e3182408812
– volume-title: Global strategy towards eliminating cervical cancer as a public health problem
  year: 2019
  ident: 4790_CR58
– volume: 8
  start-page: 755
  issue: 5
  year: 1997
  ident: 4790_CR1
  publication-title: Cancer Causes Control
  doi: 10.1023/A:1018435522475
– volume-title: Health education planning: a diagnostic approach
  year: 1980
  ident: 4790_CR42
– volume: 24
  start-page: 773
  issue: 5
  year: 2015
  ident: 4790_CR51
  publication-title: Cancer Epidemiol Biomark Prev
  doi: 10.1158/1055-9965.EPI-14-0998
– volume: 320
  start-page: 674
  issue: 7
  year: 2018
  ident: 4790_CR25
  publication-title: JAMA.
  doi: 10.1001/jama.2018.8024
– volume: 11
  start-page: e0151978
  issue: 4
  year: 2016
  ident: 4790_CR23
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0151978
– volume: 121
  start-page: 829
  issue: 4
  year: 2013
  ident: 4790_CR45
  publication-title: Obstet Gynecol
  doi: 10.1097/AOG.0b013e3182883a34
– volume: 36
  start-page: 46
  issue: 1
  year: 2014
  ident: 4790_CR24
  publication-title: J Public Health
  doi: 10.1093/pubmed/fdt057
– volume: 85
  start-page: 791
  issue: 6
  year: 1995
  ident: 4790_CR6
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.85.6.791
– volume: 95
  start-page: 103208
  year: 2019
  ident: 4790_CR48
  publication-title: J Biomed Inform
  doi: 10.1016/j.jbi.2019.103208
– volume: 18
  start-page: 1028
  issue: 12
  year: 2003
  ident: 4790_CR8
  publication-title: J Gen Intern Med
  doi: 10.1111/j.1525-1497.2003.20807.x
– volume: 81
  start-page: 207
  issue: 3
  year: 2005
  ident: 4790_CR26
  publication-title: Sex Transm Infect
  doi: 10.1136/sti.2004.011858
– volume: 25
  start-page: 807
  issue: 5
  year: 2016
  ident: 4790_CR50
  publication-title: Cancer Epidemiol Biomark Prev
  doi: 10.1158/1055-9965.EPI-15-1044
– volume: 12
  start-page: 111
  issue: 1
  year: 2017
  ident: 4790_CR40
  publication-title: Implement Sci
  doi: 10.1186/s13012-017-0640-6
– volume: 151
  start-page: 1158
  issue: 12
  year: 2000
  ident: 4790_CR53
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a010166
– volume: 98
  start-page: 723
  issue: 7
  year: 2011
  ident: 4790_CR18
  publication-title: Bull Cancer
  doi: 10.1684/bdc.2011.1388
– volume: 64
  start-page: 77
  year: 2018
  ident: 4790_CR28
  publication-title: Contemp Clin Trials
  doi: 10.1016/j.cct.2017.11.004
– volume: 4
  start-page: 50
  issue: 1
  year: 2009
  ident: 4790_CR41
  publication-title: Implement Sci
  doi: 10.1186/1748-5908-4-50
– volume: 101
  start-page: 871
  issue: 5
  year: 2009
  ident: 4790_CR16
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605194
– volume: 97
  start-page: 426
  issue: 3
  year: 2014
  ident: 4790_CR44
  publication-title: Patient Educ Couns
  doi: 10.1016/j.pec.2014.09.003
– volume: 113
  start-page: 2855
  issue: 10 Suppl
  year: 2008
  ident: 4790_CR31
  publication-title: Cancer.
  doi: 10.1002/cncr.23756
– ident: 4790_CR60
– volume: 20
  start-page: 1960
  issue: 9
  year: 2011
  ident: 4790_CR19
  publication-title: Cancer Epidemiol Biomark Prev
  doi: 10.1158/1055-9965.EPI-11-0307
– volume: 104
  start-page: 248
  issue: 2
  year: 2011
  ident: 4790_CR15
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6606040
– volume: 42
  start-page: 377
  issue: 2
  year: 2009
  ident: 4790_CR47
  publication-title: J Biomed Inform
  doi: 10.1016/j.jbi.2008.08.010
– volume: 119
  start-page: 1095
  issue: 5
  year: 2006
  ident: 4790_CR54
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21955
– volume: 100
  start-page: 243
  year: 2017
  ident: 4790_CR4
  publication-title: Prev Med
  doi: 10.1016/j.ypmed.2017.05.004
– volume-title: SEER cancer statistics review, 1975-2012
  year: 2015
  ident: 4790_CR5
– volume: 61
  start-page: 258
  year: 2012
  ident: 4790_CR32
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 280
  start-page: 112513
  year: 2019
  ident: 4790_CR39
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2019.112513
– volume: 375
  start-page: 1790
  issue: 18
  year: 2016
  ident: 4790_CR30
  publication-title: N Engl J Med
  doi: 10.1056/NEJMhpr1608578
– volume: 61
  start-page: 237
  issue: 4
  year: 2011
  ident: 4790_CR36
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20111
– volume: 125
  start-page: 330
  issue: 2
  year: 2015
  ident: 4790_CR46
  publication-title: Obstet Gynecol
  doi: 10.1097/AOG.0000000000000669
– volume: 66
  start-page: 201
  issue: 8
  year: 2017
  ident: 4790_CR3
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6608a1
– volume: 16
  start-page: 835
  issue: 1
  year: 2016
  ident: 4790_CR21
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2859-z
– volume-title: America’s health care safety net: intact but endangered
  year: 2000
  ident: 4790_CR29
– volume: 21
  start-page: e255
  issue: 2
  year: 2014
  ident: 4790_CR12
  publication-title: Curr Oncol
  doi: 10.3747/co.21.1720
– volume: 8
  start-page: 117
  issue: 1
  year: 2013
  ident: 4790_CR38
  publication-title: Implement Sci
  doi: 10.1186/1748-5908-8-117
– volume: 12
  start-page: e0172548
  issue: 2
  year: 2017
  ident: 4790_CR33
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0172548
– volume: 64
  start-page: 108
  year: 2014
  ident: 4790_CR9
  publication-title: Prev Med
  doi: 10.1016/j.ypmed.2014.04.011
– volume: 30
  start-page: 6016
  issue: 42
  year: 2012
  ident: 4790_CR2
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2012.07.056
– ident: 4790_CR52
– volume: 340
  start-page: c1040
  year: 2010
  ident: 4790_CR13
  publication-title: BMJ.
  doi: 10.1136/bmj.c1040
– volume: 83
  start-page: 139
  issue: 2
  year: 2006
  ident: 4790_CR34
  publication-title: J Urban Health
  doi: 10.1007/s11524-006-9030-0
– volume: 35
  start-page: S34
  issue: 1 Suppl
  year: 2008
  ident: 4790_CR35
  publication-title: Am J Prev Med
  doi: 10.1016/j.amepre.2008.04.002
– volume: 130
  start-page: 1128
  issue: 5
  year: 2012
  ident: 4790_CR14
  publication-title: Int J Cancer
  doi: 10.1002/ijc.26128
– volume: 63
  start-page: 1004
  issue: 44
  year: 2014
  ident: 4790_CR7
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 13
  start-page: E154
  year: 2016
  ident: 4790_CR10
  publication-title: Prev Chronic Dis
  doi: 10.5888/pcd13.160225
– volume: 105
  start-page: 337
  issue: 3
  year: 2011
  ident: 4790_CR17
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.236
– volume: 120
  start-page: 1505
  issue: 7
  year: 2007
  ident: 4790_CR20
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22484
– volume: 11
  start-page: 1048
  issue: 11
  year: 2010
  ident: 4790_CR49
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70230-8
SSID ssj0043934
ssj0017864
Score 2.304329
Snippet Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based...
Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening....
Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based...
BackgroundAlmost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based...
Abstract Background Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 872
SubjectTerms Biomedicine
Cancer screening
Cervical cancer
Cervical cancer screening
Clinical trials
Cost analysis
Cultural differences
Design
Diagnosis
Disease prevention
Early Detection of Cancer
Ethnicity
Evaluation
Female
Health care access
Health care policy
Health Sciences
Hispanic Americans
Human papillomavirus
Humans
Hybrid effectiveness-implementation designs
Hybrid type 2 designs
Intervention
Literacy
Mass Screening
Medical screening
Medical testing products
Medicine
Medicine & Public Health
Methods
Minority & ethnic groups
Minority Groups
Pap smear
Papillomaviridae
Papillomavirus infections
Papillomavirus Infections - diagnosis
Patient navigation
Patients
Pragmatic trials
Preventive medicine
Prospective Studies
Randomized Controlled Trials as Topic
Self-sample HPV testing
Statistics for Life Sciences
Study Protocol
Uterine Cervical Neoplasms - diagnosis
Womens health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBRkJiQNEjfPwg1tBVCukIg4F9WY5E5tGtFnUpIf2h_H7mHGSpSkCLlzXk2hifzOeWY-_YeyFkEECGJOi81dpWUufOlEQbWVVmNCAqWI7n4OPcvW5_HBUHV1p9UU1YSM98DhxuxJELqSTdYGBvUab8LXDt4cacpDSRO-bmWxOpkYfjLtsUc5XZLTc7dFTx_NKKmVUJkurxTYU2fp_98lXNqXrBZPXTk3jZrR_h92eoki-N2q_zW747i67eTCdk99jP6h0wje89ych7R0xAPPVpy98IE6N7iv_1g49H9a8jX8peA7RY-AbgUBwxtGXYH5Lkm3HHe9d8MMF7_zAx3uTfCSAfsOJ5mGNWOIY-6Lg8QVdAONjkcjkR9P2dK5RJxBw3Byb9Wl7iepNdfKkaewecp8d7r8_fLdKpw4NKchMDakwdQmVqI3PsqBANVqDCyoUrvJB-RwElNBgSiQbHVxZmzwoIuwnvvKm1MUDttWtO_-I8doJwOBN1UJBqcpgMI6UuS8w38y0hyJhYl4vCxN7OTXROLExi9HSjmtscY1tXGNbJezV5pnvI3fHX6XfEgw2ksS7HX9ANNoJjfZfaEzYSwKRJe-A6oGbLjngRxLPlt3DgLCKLdQTtrOQRKuG5fAMQzt5ld7mGI0R1abRCXu-GaYnqVKu8-tzlEEjk7pCG0jYwxG1m08qiP4RFU-YWuB58c3Lka49jpzjmFZSOJ6w1zPyf6n15zl9_D_m9Am7lZPlYsCQix22NZyd-6cYCQ71s2j0PwFUAVtJ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2gICMhcYCo6zz84IIKolohFXEoaG-W49ht1DYpm_RQfhi_jxnH2ZIieo0nkR3PfJ6xx98Q8ppxz61VKgXwF2lRcZcaliNtZZkrX1tVhnI--1_58nvxZVWu4oZbH9MqJ0wMQF13FvfIdzJYiZBmUMkPZz9TrBqFp6uxhMZNcouBJ4KlG8RqE3AxIXkxXZSRfKcHvA6nlpjQKNQiLWeLUeDs_xeZ_1qarqZNXjk7DUvS3j1yN_qSdHec_PvkhmsfkNv78bT8IfmNCRSupr078WlvkAeYLr_9oAMya7SH9LgZejp0tAkbC47agBvwRYuqsKaAKBDlomTTUkN7491wQVs30PH2JB1poN9TJHvoQKMoeMAgeHSB18DomCoS0TRtTqdMdVQFCktk3Z02v6B7MVseexpqiDwiB3ufDz4t01inIbV8IYaUqaqwJauUWyy8sKKW0hovfG5K54XLLLOFrSEw4rX0pqhU5gXS9iNreV3I_DHZarvWPSW0MsyCCycqJmwhCq_Am-SZyyHqXEhn84Swab60jRzmWErjRIdYRnI9zrGGOdZhjnWZkLebd85GBo9rpT-iGmwkkX07POjWhzoas-aWZYwbXuUQbErAaVcZ0Hhf2cxyrrKEvEEl0ogR0D1r4lUHGCSybeldcAvLUEg9IdszSbBtO2-e1FBHbOn1pSUk5NWmGd_EfLnWdecgA6bGZQkImJAno9ZuhpQjCSR0PCFips-zMc9b2uYoMI9DcIlOeULeTZp_2a3__9Nn14_iObmToU2CQ5CxbbI1rM_dC_D0huplMOc_NcFSsg
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9UwELagSIgLYidQkJGQOEDEcxYv3EpF9YRUxKGg3ixnYtOINkFNeig_jN_HjJM8mrJIXONxZGf2ePwNY8-FDBLAmBSNv0qLSvrUiZxgK8vchBpMGdv57H-Q60_F-8PycILJobswF8_vhZave7Sx8aSRihCVWaXlVXatpId0MCt3Z6uLfjUv5ksxf5y3cDwRn_93K3zBDV0ukbx0Thrdz94tdnOKG_nOyOjb7Ipv77Dr-9PJ-F32g4olfM17fxzS3hHmL19__MwHQtFov_CvzdDzoeNN_IngOUQbgW8EYvspR-uBGS1RNi13vHfBD-e89QMfb0ryEfL5DSdghw6lh2O0i4RH53Tli49lIZPlTJuTuSqd2M7RHdbdSfMdlzdVxtNKY7-Qe-xg793B7jqdejKkIFdqSIWpCihFZfxqFRSoWmtwQYXclT4on4GAAmpMgmStgysqkwVFEP2EUF4XOr_Pttqu9Q8Zr5wADNdUJRQUqggGI0eZ-RwzzJX2kCdMzPyyMOGVU9uMYxvzFi3tyGOLPLaRx7ZM2MvNnG8jWsc_qd-SGGwoCWk7PkABtJPiWgkiE9LJKsfEUqNN9pVD6Q4VZCClyRL2goTIkj3A5YGbrjXgJglZy-5gCFjGpukJ215Qoh7DcngWQzvZkd5mGH8RuKbRCXu2GaaZVBvX-u4MaVCtpC5RBxL2YJTazZZyAnzEhSdMLeR5seflSNscRZRxTCQpAE_Yq1nyfy3r79_00f-RP2Y3MtJRDAYysc22htMz_wSjvKF6GtX7J3zeS4g
  priority: 102
  providerName: Springer Nature
Title Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial
URI https://link.springer.com/article/10.1186/s13063-020-04790-5
https://www.ncbi.nlm.nih.gov/pubmed/33087164
https://www.proquest.com/docview/2812313298
https://www.proquest.com/docview/2453685004
https://pubmed.ncbi.nlm.nih.gov/PMC7580009
https://doaj.org/article/6c1216a6b31648088eba6ccfbc2c6692
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9RAFB56AfFFvDe1LiMIPmh0J5eZRBDZLq3LQkvRruzbkExm2uA2qZsUXH-Yv89zJslqahVfEshMwlzONefMdwh5zrjhSsWxC8JfuEHKtZswH2ErQz82mYpDW87n6JhPZsF0Hs43SFfuqF3A6kbXDutJzZaL19--rt4Dw7-zDB_xNxXIYRuNxERFEQ_dcJNs23gRpvIF66gC6N4mygwDcTnouu4QzY3f6Ckqi-f_p9T-TW1dT6m8Fle16urwLrnT2pl01BDGPbKhi_vk1lEbSX9AfmByhc5opRfGrRLECKaTk8-0RtSN4ox-yeuK1iXN7U8HTZWVKfBFhWSypCBtwAPGnnlBE1olRtcrWuiaNicraQMR_ZYiEEQJ1EbBOoaO5ys8IkabNJJW0rr5RZfFjmRCQX1m5UX-HYbXZtLjSG19kYfk9PDgdDxx2xoOruJDUbssTgMVsjTWw6ERSmRRpBIjjJ-E2gjtKaYClYHTxLPIJEEae0YgpD8immdB5D8iW0VZ6B1C04QpMO9EyoQKRGBisDS5p33wSIeRVr5DWLdfUrX45lhmYyGtnxNx2eyxhD2Wdo9l6JCX63cuG3SPf_beRzJY90RkbvugXJ7JltElV8xjPOGpD45oBDJcpwlwg0mVpziPPYe8QCKSSNEwPJW0xyBgkojEJUdgMoa2yLpD9no9ge9Vv7kjQ9mxjfTAXkMwzjhyyLN1M76JuXSFLq-gD7Ahj0LgB4c8bqh2PSUfASJh4A4RPXruzbnfUuTnFpUcHE802B3yqqP8X8P6-5ru_vdyPCG3PWRPsBs8tke26uWVfgoGYZ0OyKaYiwHZHo2mn6Zw3z84PvkIT8d8PLA_WeD6Yc4GVhrAdeaNfgJwimOU
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiDeBAkYCcYCom5edIFWohVZb2l1VqKDeLMex24g2KZtUaPlh3PhvzDjOli2it143k8jeGX8zY4-_IeRlwAxTKst8AH_uxznTvgwipK1MoswUKktsO5_xhI2-xJ8OkoMl8ru_C4NllT0mWqAuaoV75KsheCKkGczS96fffewahaerfQsN6VorFGuWYsxd7NjRsx-QwjVr2x9B36_CcGtz_8PId10GfMWGvPWDLI9VEuSZHg4NV7xIUyUNN5FMtOE6VIGKVQFhPStSI-M8Cw1H0nnk3C7iNILPXiPLMe6fDMjyxuZk7_P8GIOnLO5v6qRstQGHYY9NsaKSZ0M_WfCGtmnAv67hL994sW7zwuGt9Ylbt8ktF8zS9c767pAlXd0l18fuuP4e-YUVHLqgjT42fiORiJiO9r7SFqk9qkP6rWwb2ta0tDsbmioLXPBFhbY4pQBpkGajZFlRSRtpdDujlW5pd32TdjzU7yiyTdRg0hRCcBA8muE9NNrVqjg498uTvlQebZGCjy7qk_InDM-V6-NIbROT-2T_KlT4gAyqutKPCM1loMCAeB5wFfPYZBDOslBHkPYOU60ijwS9voRyJOrYy-NY2GQqZaLTsQAdC6tjkXjkzfyd045C5FLpDTSDuSTSf9sf6umhcGgimArCgEmWR5DtpuAodC5hyZlchYqxLPTIazQigSAFw1PS3bWASSLdl1iHuDSxndw9srIgCeCiFh_3ZigcuDXifCl65MX8Mb6JBXuVrs9ABtY6SxOAYI887Kx2PqUIWShh4B7hC_a8MOfFJ1V5ZKnPIbvFrMAjb3vLPx_W___Tx5fP4jm5Mdof74rd7cnOE3IzxPUJ0UkYrJBBOz3TTyHsbPNnbnFTIq4YTv4Aw7-WJA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKK1VcEP8EChgJxAGi3fzZCVKFWtpVS-lqhQrqzXIcu41ok7JJhZYH4x14K2YcZ8sW0Vuvayeyd8bfzMQz3xDyMmCGKZVlPoA_9-OcaV8GEdJWJlFmCpUltp3P_pjtfIk_HiaHS-R3XwuDaZU9JlqgLmqF38gHIVgipBnM0oFxaRGTrdH7s-8-dpDCm9a-nYZ0bRaKdUs35oo89vTsB4RzzfruFsj-VRiOtg8-7Piu44Cv2JC3fpDlsUqCPNPDoeGKF2mqpOEmkok2XIcqULEqwMVnRWpknGeh4UhAj_zbRZxG8NobZIWD0Yc4cGVzezz5PL_S4CmL-6qdlA0aMB72ChWzK3k29JMFy2gbCPxrJv6yk5dzOC9d5Fr7OLpNbjnHlm50mniHLOnqLlndd1f398gvzObQBW30ifEbiaTEdGfylbZI81Ed0W9l29C2pqX9yqGpsiAGb1Sol1MK8AYhN84sKyppI41uZ7TSLe1KOWnHSf2OIvNEDepNwR2HicczrEmjXd6Kg3a_PO3T5lEvKdjroj4tf8LyXOo-rtQ2NLlPDq5DhA_IclVX-hGhuQwUKBDPA65iHpsMXFsW6ghC4GGqVeSRoJeXUI5QHft6nAgbWKVMdDIWIGNhZSwSj7yZP3PW0YlcOXsT1WA-E6nA7Q_19Eg4ZBFMBWHAJMsjiHxTMBo6l3D8TK5CxVgWeuQ1KpFAwILlKenqLmCTSP0lNsBHTWxXd4-sLcwEoFGLw70aCgd0jbg4lh55MR_GJzF5r9L1OcyBc8_SBODYIw87rZ1vKUJGSli4R_iCPi_seXGkKo8tDTpEuhgheORtr_kXy_r_f_r46l08J6sAK-LT7njvCbkZ4vEERyUM1shyOz3XT8EDbfNn7mxTIq4ZTf4ACc6aaA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mailed+self-sample+HPV+testing+kits+to+improve+cervical+cancer+screening+in+a+safety+net+health+system%3A+protocol+for+a+hybrid+effectiveness-implementation+randomized+controlled+trial&rft.jtitle=Trials&rft.au=Montealegre%2C+Jane+R&rft.au=Anderson%2C+Matthew+L&rft.au=Hilsenbeck%2C+Susan+G&rft.au=Chiao%2C+Elizabeth+Y&rft.date=2020-10-21&rft.pub=BioMed+Central+Ltd&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-020-04790-5&rft.externalDocID=A639522295
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon